PE20140604A1 - Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa - Google Patents
Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativaInfo
- Publication number
- PE20140604A1 PE20140604A1 PE2013002816A PE2013002816A PE20140604A1 PE 20140604 A1 PE20140604 A1 PE 20140604A1 PE 2013002816 A PE2013002816 A PE 2013002816A PE 2013002816 A PE2013002816 A PE 2013002816A PE 20140604 A1 PE20140604 A1 PE 20140604A1
- Authority
- PE
- Peru
- Prior art keywords
- ruxolitinib
- panobinostat
- treatment
- cancer
- combination
- Prior art date
Links
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 title abstract 2
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 title abstract 2
- 229960005184 panobinostat Drugs 0.000 title abstract 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 title abstract 2
- 229960000215 ruxolitinib Drugs 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 2
- 201000011510 cancer Diseases 0.000 title 1
- 230000002071 myeloproliferative effect Effects 0.000 title 1
- 230000009826 neoplastic cell growth Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 abstract 1
- 108010033040 Histones Proteins 0.000 abstract 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 abstract 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN COMPUESTO INHIBIDOR DE JAK QUE ES (R)-3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-3-CICLOPENTILPROPANONITRILO (RUXOLITINIB) EL CUAL SE ADMINISTRA 10 A 20 MG DOS VECES AL DIA; Y B) UN COMPUESTO INHIBIDOR DE HISTONA DESACETILASA (HDAC) QUE ES N-HIDROXI-3-[4-[[[2-(2-METIL-1H-INDOL-3-IL)-ETIL]-AMINO]METIL]FENIL]-2E-2-PROPENAMIDA (PANOBINOSTAT) EL CUAL SE ADMINISTRA 10 A 30 MG TRES VECES A LA SEMANA CADA DOS SEMANAS; EN DONDE LOS COMPUESTOS ESTAN EN FORMULACIONES SEPARADAS O UNITARIAS. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE LEUCEMIA MIELOIDE CRONICA, POLICITEMIA VERA, TROMBOCITEMIA ESENCIAL, MIELOFIBROSIS PRIMARIA, LEUCEMIA NEUTROFILICA CRONICA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161496750P | 2011-06-14 | 2011-06-14 | |
| US201161568717P | 2011-12-09 | 2011-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140604A1 true PE20140604A1 (es) | 2014-05-13 |
Family
ID=47357438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002816A PE20140604A1 (es) | 2011-06-14 | 2012-06-13 | Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20140113919A1 (es) |
| EP (1) | EP2720696B1 (es) |
| JP (1) | JP6200884B2 (es) |
| KR (1) | KR20140056212A (es) |
| CN (1) | CN103608012A (es) |
| AU (2) | AU2012271814A1 (es) |
| BR (1) | BR112013032125A2 (es) |
| CA (1) | CA2844407A1 (es) |
| CL (1) | CL2013003577A1 (es) |
| CO (1) | CO6821954A2 (es) |
| EA (1) | EA027654B1 (es) |
| ES (1) | ES2595407T3 (es) |
| GT (1) | GT201300308A (es) |
| IL (1) | IL229766A (es) |
| MX (1) | MX344580B (es) |
| NZ (1) | NZ618367A (es) |
| PE (1) | PE20140604A1 (es) |
| PH (1) | PH12013502523A1 (es) |
| SG (1) | SG195141A1 (es) |
| WO (1) | WO2012174061A1 (es) |
| ZA (1) | ZA201308815B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| ES2834093T3 (es) | 2011-07-21 | 2021-06-16 | Sumitomo Dainippon Pharma Oncology Inc | Inhibidores de proteína quinasa heterocíclicos |
| MX354725B (es) | 2011-11-11 | 2018-03-16 | Novartis Ag | Metodo de tratamiento de una enfermedad proliferativa. |
| SG11201401260QA (en) | 2011-11-23 | 2014-07-30 | Novartis Ag | Pharmaceutical formulations |
| HK1214765A1 (zh) * | 2012-11-08 | 2016-08-05 | Novartis Ag | 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途 |
| JP6479818B2 (ja) * | 2013-05-10 | 2019-03-06 | シーエヌアイシー ファンデーション セントロ ナショナル デ インベスティゲイショネス カーディオバスキュレアス カルロス ザ サード | 骨髄増殖性新生物の治療に適した化合物 |
| EP3148545B1 (en) | 2014-05-28 | 2023-03-15 | Onco Tracker, Inc. | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| ES2874537T3 (es) * | 2014-08-21 | 2021-11-05 | Ratiopharm Gmbh | Sal oxalato de ruxolitinib |
| KR102496025B1 (ko) * | 2014-09-22 | 2023-02-03 | 고쿠리츠켄큐카이하츠호진 카가쿠기쥬츠신코키코 | 항인플루엔자 바이러스제, 및 항인플루엔자 바이러스제의 스크리닝 방법 |
| CZ2014773A3 (cs) * | 2014-11-10 | 2016-05-18 | Zentiva, K.S. | Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu |
| RU2717829C2 (ru) | 2015-04-20 | 2020-03-26 | Толеро Фармасьютикалз, Инк. | Прогнозирование ответа на альвоцидиб с помощью анализа профиля митохондрий |
| ES2739749T3 (es) | 2015-05-18 | 2020-02-03 | Tolero Pharmaceuticals Inc | Profármacos de alvocidib que tienen biodisponibilidad aumentada |
| US10512642B2 (en) | 2015-06-04 | 2019-12-24 | Children's Hospital Medical Center | Therapeutic targeting of myeloproliferative neoplasms by DUSP1 inhibition |
| CN108289861B (zh) | 2015-08-03 | 2021-11-02 | 大日本住友制药肿瘤公司 | 用于治疗癌症的组合疗法 |
| WO2017196261A1 (en) * | 2016-05-11 | 2017-11-16 | National University Of Singapore | Jak and hdac dual-inhibitor compounds |
| WO2017209766A1 (en) * | 2016-06-03 | 2017-12-07 | Q3 Medical Devices Limited | Stent |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| KR20200143454A (ko) * | 2018-04-13 | 2020-12-23 | 스미토모 다이니폰 파마 온콜로지, 인크. | 골수증식성 신생물 및 암과 연관된 섬유증의 치료를 위한 pim 키나제 억제제 |
| WO2020068754A1 (en) * | 2018-09-25 | 2020-04-02 | Impact Biomedicines, Inc. | Methods of treating myeloproliferative disorders |
| KR20210132007A (ko) * | 2018-12-24 | 2021-11-03 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 피롤로피리미딘 화합물의 치료 용도 및 피롤로피리미딘 화합물의 고체 약학적 조성물 |
| KR102904026B1 (ko) | 2019-02-12 | 2025-12-26 | 스미토모 파마 아메리카, 인크. | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 |
| AU2020388638A1 (en) * | 2019-11-22 | 2022-06-30 | Incyte Corporation | Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor |
| WO2021154976A1 (en) * | 2020-01-28 | 2021-08-05 | Secura Bio, Inc. | Methods of treating brain cancer with panobinostat |
| CN111407894B (zh) * | 2020-02-21 | 2022-04-29 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种治疗复发/难治t细胞淋巴瘤的新型联合靶向药物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| SI3184526T1 (sl) | 2005-12-13 | 2019-03-29 | Incyte Holdings Corporation | Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze |
| CA2677651A1 (en) * | 2007-02-15 | 2008-08-21 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| MX2009013402A (es) * | 2007-06-13 | 2010-02-24 | Incyte Corp | Sales de inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]piri midin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo. |
| CA2827673C (en) * | 2011-02-18 | 2020-10-27 | Novartis Pharma Ag | Mtor/jak inhibitor combination therapy |
-
2012
- 2012-06-13 EP EP12730099.4A patent/EP2720696B1/en active Active
- 2012-06-13 PH PH1/2013/502523A patent/PH12013502523A1/en unknown
- 2012-06-13 WO PCT/US2012/042174 patent/WO2012174061A1/en not_active Ceased
- 2012-06-13 ES ES12730099.4T patent/ES2595407T3/es active Active
- 2012-06-13 US US14/123,855 patent/US20140113919A1/en not_active Abandoned
- 2012-06-13 KR KR1020147000599A patent/KR20140056212A/ko not_active Ceased
- 2012-06-13 CN CN201280029599.0A patent/CN103608012A/zh active Pending
- 2012-06-13 NZ NZ618367A patent/NZ618367A/en not_active IP Right Cessation
- 2012-06-13 EA EA201490016A patent/EA027654B1/ru not_active IP Right Cessation
- 2012-06-13 PE PE2013002816A patent/PE20140604A1/es not_active Application Discontinuation
- 2012-06-13 JP JP2014515936A patent/JP6200884B2/ja not_active Expired - Fee Related
- 2012-06-13 MX MX2013014805A patent/MX344580B/es active IP Right Grant
- 2012-06-13 AU AU2012271814A patent/AU2012271814A1/en not_active Abandoned
- 2012-06-13 SG SG2013087002A patent/SG195141A1/en unknown
- 2012-06-13 BR BR112013032125A patent/BR112013032125A2/pt not_active IP Right Cessation
- 2012-06-13 CA CA2844407A patent/CA2844407A1/en not_active Abandoned
-
2013
- 2013-11-22 ZA ZA2013/08815A patent/ZA201308815B/en unknown
- 2013-12-02 IL IL229766A patent/IL229766A/en not_active IP Right Cessation
- 2013-12-11 CO CO13290159A patent/CO6821954A2/es not_active Application Discontinuation
- 2013-12-12 GT GT201300308A patent/GT201300308A/es unknown
- 2013-12-13 CL CL2013003577A patent/CL2013003577A1/es unknown
-
2017
- 2017-06-29 AU AU2017204469A patent/AU2017204469A1/en not_active Abandoned
- 2017-10-06 US US15/726,541 patent/US20180085371A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA027654B1 (ru) | 2017-08-31 |
| MX344580B (es) | 2016-12-20 |
| GT201300308A (es) | 2017-09-28 |
| AU2012271814A1 (en) | 2013-12-12 |
| CN103608012A (zh) | 2014-02-26 |
| IL229766A0 (en) | 2014-01-30 |
| JP2014517039A (ja) | 2014-07-17 |
| WO2012174061A1 (en) | 2012-12-20 |
| US20180085371A1 (en) | 2018-03-29 |
| NZ618367A (en) | 2016-01-29 |
| SG195141A1 (en) | 2013-12-30 |
| AU2017204469A1 (en) | 2017-07-20 |
| IL229766A (en) | 2017-10-31 |
| ZA201308815B (en) | 2014-07-30 |
| PH12013502523A1 (en) | 2019-10-11 |
| JP6200884B2 (ja) | 2017-09-20 |
| US20140113919A1 (en) | 2014-04-24 |
| EA201490016A1 (ru) | 2014-04-30 |
| CL2013003577A1 (es) | 2014-08-01 |
| KR20140056212A (ko) | 2014-05-09 |
| HK1193045A1 (zh) | 2014-09-12 |
| BR112013032125A2 (pt) | 2016-12-13 |
| EP2720696A1 (en) | 2014-04-23 |
| ES2595407T3 (es) | 2016-12-29 |
| CA2844407A1 (en) | 2012-12-20 |
| EP2720696B1 (en) | 2016-05-25 |
| CO6821954A2 (es) | 2013-12-31 |
| MX2013014805A (es) | 2014-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140604A1 (es) | Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa | |
| EA201491607A1 (ru) | Модуляторы толлподобных рецепторов | |
| EA201591662A1 (ru) | Липиды и липидные композиции для доставки активных агентов | |
| CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
| CO6690768A2 (es) | Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7 | |
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
| EA200971115A1 (ru) | Новые ингибиторы обратной транскриптазы вич | |
| CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
| EA201690247A1 (ru) | Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| EA201590200A1 (ru) | Модуляторы пути активации комплемента и их применение | |
| UY32156A (es) | Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones. | |
| EA201492281A1 (ru) | Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
| EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
| EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| EA201591177A1 (ru) | Трициклические соединения для ингибирования канала cftr | |
| UY33278A (es) | Pirimidinas sustituidas como antagonistas del receptor de la protaglandina d2 | |
| MX2014007878A (es) | Formulaciones de (+) - 2 - [1 - (3 - etoxi - 4 - metoxi - fenil) - 2 - metansulfonil - etil] - 4 - acetil aminoisoindolin - 1, 3 - diona. | |
| EA201591649A1 (ru) | Составы с органическими соединениями | |
| UY35209A (es) | Compuestos tricíclicos | |
| EA201001882A1 (ru) | Гидроксизамещенные тиенопиримидиноны как антагонисты рецептора-i меланинконцентрирующего гормона | |
| EA201391124A1 (ru) | Новые бензодиоксолпиперазиновые соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |